CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

CVRx (NASDAQ:CVRX) issued its quarterly earnings results on Monday. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.01, Zacks reports. CVRx had a negative net margin of 89.14% and a negative return on equity of 108.72%. The company had revenue of $14.77 million for the quarter, compared to the consensus estimate of $14.49 million.

Here are the key takeaways from CVRx’s conference call:

• CVRx reported a strong Q1, with total revenue of $14.8 million (+20%), U.S. revenue of $13.7 million (+22%), an improved gross margin of 87%, and a slightly smaller net loss, signaling that prior investments are beginning to drive commercial results.
• The transition to Category I CPT codes is a major reimbursement win, but new Medicare Advantage rules and payer automation produced a March dip in 30?day prior?authorization approvals (Q1 rate 46%), creating a near?term administrative headwind that may add variability to access and timing of revenue.
• The BENEFIT?HF randomized trial is underway (first site activated, first patient enrolled) and, if successful, could expand the addressable market from ~339,000 to >980,000 patients (~$30 billion TAM), although regulatory and enrollment timelines extend over several years.
• Commercial execution is improving — U.S. territories increased to 56 and active implanting centers to 257, and management reports higher utilization at targeted centers driven by a program?focused sales approach, supporting sustained U.S. growth.
• Management reaffirmed 2026 guidance (revenue $63–67M, gross margin 85–87%, operating expenses $103–107M) despite the Q1 beat, reflecting a cautious posture early in the year while monitoring reimbursement and trial rollout trends.

CVRx Trading Up 2.0%

Shares of CVRX traded up $0.10 during midday trading on Wednesday, reaching $5.37. The company had a trading volume of 331,160 shares, compared to its average volume of 333,156. CVRx has a 1-year low of $4.37 and a 1-year high of $11.30. The stock has a market cap of $142.01 million, a PE ratio of -2.66 and a beta of 0.90. The firm has a 50 day simple moving average of $7.96 and a 200-day simple moving average of $7.97. The company has a quick ratio of 6.72, a current ratio of 7.63 and a debt-to-equity ratio of 1.26.

Insider Activity

In related news, Director Mudit K. Jain bought 46,800 shares of the business’s stock in a transaction on Friday, February 20th. The stock was acquired at an average cost of $6.36 per share, with a total value of $297,648.00. Following the purchase, the director directly owned 980,183 shares of the company’s stock, valued at $6,233,963.88. The trade was a 5.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 18.90% of the stock is owned by company insiders.

Institutional Trading of CVRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of CVRx during the 4th quarter worth about $79,000. Corient Private Wealth LLC acquired a new stake in shares of CVRx during the 4th quarter worth about $81,000. XTX Topco Ltd acquired a new stake in shares of CVRx during the 4th quarter worth about $90,000. Alliancebernstein L.P. grew its position in CVRx by 10.7% in the 3rd quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in CVRx by 61.3% in the 4th quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock valued at $144,000 after acquiring an additional 7,705 shares in the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price target on shares of CVRx in a report on Tuesday, April 14th. Weiss Ratings downgraded shares of CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, Cantor Fitzgerald upgraded shares of CVRx to a “strong-buy” rating in a report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CVRx currently has a consensus rating of “Buy” and a consensus price target of $11.50.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.